Filters

Pp-240 manufacturers

Filters

None products found

pp-240

Injection

Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: IgA Nephropathy (IgAN), Anti-PLA2R MPGN, FSGS, Minimal Change Disease, Lupus Nephritis / Clinical stage: Phase 3 / Modality: Biologic - fusion protein (BAFF/APRIL antagonist) / Mechanism & Target: Dual BAFF/APRIL inhibition for B-cell modulation / Route & form: SC once weekly / Differentiation: First-in-class B-cell modulator in IgAN; home-administered
Manufacturer #39443
Clinical-stage biopharmaceutical company focused on autoimmune kidney diseases. Develops dual-targeting biologics inhibiting key mediators of IgA nephropathy and lupus nephritis. Lead Phase 3 program holds FDA Breakthrough Therapy designation.
 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.